Three SV professors among Highly Cited Researchers 2023

Andrea Ablasser, Johan Auwerx, and Michele De Palma. Credit: Alain Herzog/EPFL (Auwerx) and AGORA Cancer Research Center (De Palma).

Andrea Ablasser, Johan Auwerx, and Michele De Palma. Credit: Alain Herzog/EPFL (Auwerx) and AGORA Cancer Research Center (De Palma).

Andrea Ablasser, Johan Auwerx, and Michele De Palma, three professors at EPFL’s School of Life Sciences, have been included in the prestigious list of most Highly Cited Researchers in 2023.

The Highly Cited Researchers ranking is published each year by Clarivate to recognize scientists who have “authored multiple Highly Cited Papers™ which rank in the top 1% by citations for their field(s) and publication year in the Web of Science™ over the past decade.” Highly Cited Researchers™ account for just 1 in 1000 of the world’s scientists and social scientists.

Three professors at EPFL’s School of Life Sciences, Andrea Ablasser, Johan Auwerx, and Michele De Palma, have been included in the prestigious list of most Highly Cited Researchers in 2023.

Andrea Ablasser

Professor Ablasser’s research focuses on the identification of factors involved in the intracellular recognition of pathogen-derived molecular patterns and on the elucidation of the consecutive signaling events. She also aims towards a better understanding of the physiological functions of these pathways both in the context of pathogen infection and during non-infectious, physiological processes.

Lab: https://ablasserlab.epfl.ch

Johan Auwerx

Professor Auwerx’s research uses systems approaches to map the signaling networks that govern mitochondrial function and as such regulate organismal metabolism. His work in the fields of cellular metabolism has contributed to a better understanding of the regulation of mitochondrial function by signaling pathways in health, disease, and aging.

https://www.epfl.ch/labs/auwerx-lab/

Michele De Palma

Professor De Palma’s research focuses on the interactions between genetically altered cancer cells and the ostensibly normal host tissues in which tumors arise, progress and develop to metastatic disease. By tackling these processes, he aims to reprogram the immunosuppressive tumor microenvironment to a form that enhances the efficacy of anticancer therapies and facilitates the deployment of anti-tumor immunity. His lab is based in the Agora Cancer Research Center.

Lab: https://www.epfl.ch/labs/depalma-lab/